Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
Oral Presentations:
Title (Abstract): |
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis (#539) |
Presenter: | |
Session/Time: | Advances in Eosinophilic Esophagitis/ |
Title (Abstract): |
Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria (#779) |
Presenter: | |
Session/Time: | Atopic Dermatitis with a Side of Urticaria/ |
Featured Poster Presentations:
Title (Abstract): |
AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic Experimental COPD Model Through Mast Cell Inhibition (#568) |
Presenter: | |
Session/Time: | New Insights in Asthma Genomics and Cell Signaling/ |
Title (Abstract): |
Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study) (#593) |
Presenter: | |
Session/Time: | Headlines in Immunotherapy, Rhinitis, Sinusitis and Ocular Disease/ |
Poster Presentations:
Title (Abstract): |
Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that are Inhibited by AK002 after Stimulation Ex Vivo (#637) |
Presenter: | |
Session/Time: | Atopic Dermatitis/ |
Title (Abstract): |
EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis (#129) |
Presenter: | |
Session/Time: | Pathogenesis and Treatment of Eosinophilic Esophagitis/ |
Title (Abstract): |
A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis (#121) |
Presenter: | |
Session/Time: | Diagnosis of Eosinophilic Esophagitis/ |
Following the presentations, the posters will be available on the
About
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab (AK002) has been tested in five clinical studies. In these studies, antolimab (AK002) eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com
Source:
Investor Contact:Adam Tomasi , President & COO investors@allakos.com Media Contact:Denise Powell denise@redhousecomms.com
Source: Allakos Inc.